FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1840787574> ?p ?o ?g. }

• W1840787574 endingPage "377" @default.
• W1840787574 startingPage "370" @default.
• W1840787574 abstract "Although cytochrome P450 (CYP) 2C9 was thought to be the main pathway for glyburide (INN, glibenclamide) metabolism in vivo, studies in vitro indicated that CYP2C19 had a more dominant effect. This study investigated the relative influence of CYP2C9 and CYP2C19 genotypes on the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.Three groups of healthy male Chinese subjects (n=6 per group) were enrolled, as follows: group I, CYP2C9*1/*1 and CYP2C19 extensive metabolizers (EMs); group II, CYP2C9*1/*1 and CYP2C19 poor metabolizers (PMs); and group III, CYP2C9*1/*3 and CYP2C19 EMs. Subjects received single oral doses of 5 mg glyburide. Multiple blood samples were collected, and the plasma glyburide concentrations were determined by an HPLC method. The plasma glucose and insulin concentrations were also measured up to 2 hours after dosing.No significant differences in glyburide pharmacokinetics were observed between CYP2C19 EM and PM subjects who had the CYP2C9*1/*1 genotype (group I versus group II). Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721). However, significant increases in AUC(0-infinity) (125% and 82%; P=.008 and .024, respectively) and t1/2 (71% and 60%; P=.003 and .007, respectively) were observed when CYP2C9*1/*3 subjects (group III) were compared with CYP2C9*1/*1 subjects in group I or II. Blood glucose reductions at 2 hours after dosing were 41.8%, 23.9%, and 27.7% in groups I, II, and III, respectively (P=.029), and hypoglycemia developed in 3 of 6 CYP2C9*1/*3 carriers and 2 of 12 CYP2C9*1/*1 carriers.CYP2C9, but not CYP2C19, polymorphism appears to exert a dominant influence on glyburide pharmacokinetics and pharmacodynamics in vivo. Further studies in diabetic patients with long-term dosing are warranted to confirm these findings." @default.
• W1840787574 created "2016-06-24" @default.
• W1840787574 creator A5014245128 @default.
• W1840787574 creator A5034353627 @default.
• W1840787574 creator A5068775883 @default.
• W1840787574 date "2005-10-01" @default.
• W1840787574 modified "2023-09-22" @default.
• W1840787574 title ", but not , polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects" @default.
• W1840787574 cites W14345246 @default.
• W1840787574 cites W1550666015 @default.
• W1840787574 cites W179252842 @default.
• W1840787574 cites W1872726898 @default.
• W1840787574 cites W1967404067 @default.
• W1840787574 cites W1969535782 @default.
• W1840787574 cites W1979716218 @default.
• W1840787574 cites W1984866038 @default.
• W1840787574 cites W2002779112 @default.
• W1840787574 cites W2012407966 @default.
• W1840787574 cites W2020565396 @default.
• W1840787574 cites W2026438566 @default.
• W1840787574 cites W2038561203 @default.
• W1840787574 cites W2053475332 @default.
• W1840787574 cites W2053863013 @default.
• W1840787574 cites W2054666475 @default.
• W1840787574 cites W2074257646 @default.
• W1840787574 cites W2074651982 @default.
• W1840787574 cites W2077458212 @default.
• W1840787574 cites W2109453128 @default.
• W1840787574 cites W2114143292 @default.
• W1840787574 cites W2114346603 @default.
• W1840787574 cites W2288991238 @default.
• W1840787574 doi "https://doi.org/10.1016/j.clpt.2005.06.006" @default.
• W1840787574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16198656" @default.
• W1840787574 hasPublicationYear "2005" @default.
• W1840787574 type Work @default.
• W1840787574 sameAs 1840787574 @default.
• W1840787574 citedByCount "53" @default.
• W1840787574 countsByYear W18407875742012 @default.
• W1840787574 countsByYear W18407875742013 @default.
• W1840787574 countsByYear W18407875742014 @default.
• W1840787574 countsByYear W18407875742015 @default.
• W1840787574 countsByYear W18407875742016 @default.
• W1840787574 countsByYear W18407875742017 @default.
• W1840787574 countsByYear W18407875742018 @default.
• W1840787574 countsByYear W18407875742019 @default.
• W1840787574 countsByYear W18407875742020 @default.
• W1840787574 countsByYear W18407875742021 @default.
• W1840787574 countsByYear W18407875742022 @default.
• W1840787574 countsByYear W18407875742023 @default.
• W1840787574 crossrefType "journal-article" @default.
• W1840787574 hasAuthorship W1840787574A5014245128 @default.
• W1840787574 hasAuthorship W1840787574A5034353627 @default.
• W1840787574 hasAuthorship W1840787574A5068775883 @default.
• W1840787574 hasConcept C111113717 @default.
• W1840787574 hasConcept C112705442 @default.
• W1840787574 hasConcept C126322002 @default.
• W1840787574 hasConcept C134018914 @default.
• W1840787574 hasConcept C140840227 @default.
• W1840787574 hasConcept C185592680 @default.
• W1840787574 hasConcept C2779768347 @default.
• W1840787574 hasConcept C3946865 @default.
• W1840787574 hasConcept C526171541 @default.
• W1840787574 hasConcept C555293320 @default.
• W1840787574 hasConcept C62231903 @default.
• W1840787574 hasConcept C71924100 @default.
• W1840787574 hasConcept C76318530 @default.
• W1840787574 hasConcept C98274493 @default.
• W1840787574 hasConceptScore W1840787574C111113717 @default.
• W1840787574 hasConceptScore W1840787574C112705442 @default.
• W1840787574 hasConceptScore W1840787574C126322002 @default.
• W1840787574 hasConceptScore W1840787574C134018914 @default.
• W1840787574 hasConceptScore W1840787574C140840227 @default.
• W1840787574 hasConceptScore W1840787574C185592680 @default.
• W1840787574 hasConceptScore W1840787574C2779768347 @default.
• W1840787574 hasConceptScore W1840787574C3946865 @default.
• W1840787574 hasConceptScore W1840787574C526171541 @default.
• W1840787574 hasConceptScore W1840787574C555293320 @default.
• W1840787574 hasConceptScore W1840787574C62231903 @default.
• W1840787574 hasConceptScore W1840787574C71924100 @default.
• W1840787574 hasConceptScore W1840787574C76318530 @default.
• W1840787574 hasConceptScore W1840787574C98274493 @default.
• W1840787574 hasIssue "4" @default.
• W1840787574 hasLocation W18407875741 @default.
• W1840787574 hasLocation W18407875742 @default.
• W1840787574 hasOpenAccess W1840787574 @default.
• W1840787574 hasPrimaryLocation W18407875741 @default.
• W1840787574 hasRelatedWork W1592942416 @default.
• W1840787574 hasRelatedWork W1840787574 @default.
• W1840787574 hasRelatedWork W1966443288 @default.
• W1840787574 hasRelatedWork W1970590009 @default.
• W1840787574 hasRelatedWork W2108417615 @default.
• W1840787574 hasRelatedWork W2140817293 @default.
• W1840787574 hasRelatedWork W2469877339 @default.
• W1840787574 hasRelatedWork W2995148693 @default.
• W1840787574 hasRelatedWork W4366985951 @default.
• W1840787574 hasRelatedWork W4377967821 @default.
• W1840787574 hasVolume "78" @default.
• W1840787574 isParatext "false" @default.

• next